01—Abstract
Summary
Summary of the 8-K filed December 9, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. disclosed under Item 5.02 that its Compensation Committee approved a one-time performance-based restricted stock unit grant (the "PSU Grant") for Dr. Helen Torley, Chief Executive Officer, on December 4, 2025.
The award was made under the Company's 2021 Stock Plan and has a grant date fair value of $10 milliona, determined under U.S. GAAP using a Monte Carlo valuation model. The grant is intended to retain Dr. Torley and incentivize her to drive growth and profitability during what the filing calls the Company's "next stage of growth." The number of shares that can vest depends on the average closing price of the common stock over 20 consecutive trading days during a four-year performance period following the grant date. Vesting ranges from 50% of the target shares at an average price of $115.00 to 200% at $170.00, with 100% at $130.00 and 150% at $145.00.
If the average price never reaches $115.00b, no shares will be eligible to vest. Earned shares also require Dr. Torley's continued employment through the fourth anniversary of the grant date, subject to exceptions in the award agreement.
The filing states that voluntary resignation or retirement before the vesting date will result in forfeiture of all performance-based vested shares. The full award agreement is to be filed as an exhibit to the Company's Form 10-K for the fiscal year ending December 31, 2025.
02—Key points
Key Highlights
- CEO Dr. Helen Torley received a one-time performance-based RSU grant approved by the Compensation Committee on December 4, 2025, under the 2021 Stock Plan.
- The grant date fair value of the PSU Grant is $10 million, based on a Monte Carlo valuation model.
- Eligible vesting scales from 50% of target shares at an average price of $115.00 up to 200% at $170.00, with 100% at $130.00 and 150% at $145.00.
- No shares become eligible to vest if the average stock price never reaches $115.00 during the four-year performance period.
- Price is measured as the average of closing prices over 20 consecutive trading days.
- Earned shares vest only if Dr. Torley remains employed through the fourth anniversary of the grant date, subject to award agreement exceptions.
- Voluntary resignation or retirement before the vesting date results in forfeiture of all performance-based vested shares.
- The full award agreement will be filed as an exhibit to the Form 10-K for fiscal year 2025.
03—Questions
Frequently Asked Questions
What is the size and purpose of the CEO's PSU Grant?
The grant is a one-time performance-based RSU award to CEO Dr. Helen Torley with a grant date fair value of $10 million. The Company states it is intended to retain Dr. Torley and further incentivize her to drive growth and profitability during the next stage of growth.
What stock price levels trigger vesting under the award?
Vesting is tied to the average closing price over 20 consecutive trading days during a four-year performance period. The filing lists 50% of target shares eligible at $115.00, 100% at $130.00, 150% at $145.00, and 200% at $170.00. No shares vest if the average never reaches $115.00.
Does the award require Dr. Torley to remain employed?
Yes. Shares that become eligible based on price levels vest only if Dr. Torley remains employed through the fourth anniversary of the grant date, subject to exceptions in the applicable award agreement.
What happens if Dr. Torley resigns or retires early?
The filing states that if Dr. Torley voluntarily resigns or retires before the vesting date, all performance-based vested shares will be forfeited.
Where can investors find the full terms of the award?
The filing states that the award agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025, and that this summary is qualified in its entirety by that agreement.
04—Continue